News

According to a new study from New York Eye and Ear Infirmary of Mount Sinai, a new, non-invasive ocular imaging method may be able to detect an early indicator of glaucoma in time to prevent disease progression and vision loss.

According to EyePoint Pharmaceuticals, the clinical trial is reviewing EYP-1901, an investigational sustained delivery anti-vascular endothelial growth factor (anti-VEGF) treatment for wet age-related macular degeneration (wet AMD).

Recent reports of retinal atrophy have raised concerns on potential long-term safety.

According to the company, AR-15512 is a differentiated, novel, first-in-class product candidate for the treatment of the signs and symptoms of dry eye disease.

According to the company, the clinical trial is reviewing EYP-1901, an investigational sustained delivery anti-vascular endothelial growth factor (anti-VEGF) treatment for wet age-related macular degeneration (wet AMD).

The discovery of molecular signatures of age-related macular degeneration will help with better diagnosis and treatment of this progressive eye disease.

Retina indications for which ranibizumab-eqrn is interchangeable include neovascular (wet) age-related macular degeneration; macular edema following retinal vein occlusion; diabetic macular edema; diabetic retinopathy, and myopic choroidal neovascularization.

Several issues may restimulate the virus in those patients with prior exposure.

A novel regimen may represent an improvement over current methods of handling postsurgical pain in procedures that require corneal epithelial debridement, according to investigators.

Flavoprotein fluorescence could serve as a new biomarker, according to a Mount Sinai study.

Two studies conducted in collaboration with Orbis International explore how providing free glasses to children improves their ability to learn in school and that addressing visual impairment in children can alleviate depression and anxiety.

The discovery of molecular signatures of age-related macular degeneration will help with better diagnosis and treatment of this progressive eye disease.

Investigators discuss the evolution of innovative technology for the hearing impaired and how vision can play a role.

84% of the patients who received a hybrid, acrylic IOL with a continuous transitional focus (CTF) optic to correct presbyopia were within 0.5 D of emmetropia.

The doctors will join the Cataract and Primary Eye Care, Glaucoma, and Retina Services.

While the COVID-19 pandemic revealed the potential of utilizing artificial intelligence in screening for diabetic retinopathy, improvements are still needed as a results of the number of images that are ungradable.

A team of scientists, led by Andrzej Foik, PhD, of the International Center for Translational Eye Research, is working on new therapies that may slow vision loss in patients diagnosed with retinal degeneration.

Several issues may restimulate the virus in those patients with prior exposure.

The findings of this study may have revealed the crucial role of gene fragments in retinal development and vision.

A novel computational platform identifies top-performing viral vectors that could deliver gene therapies to the retina with maximum efficiency and precision.

The Grail study finds the device can offer positive outcomes for patients.

Bausch + Lomb has made an equity investment in Sanoculis and has entered into an exclusive European distribution agreement for MIMS minimally invasive surgical procedure.

Positive results from recent pre-clinical studies support the potential of long-acting PASylated nomacopan to advance toward IND/IMPD for clinical trials in geographic atrophy (GA) in dry age-related macular degeneration (dAMD), a disease with no approved treatments.

Treatment reduces burden of care, providing another option for patients diagnosed with diabetic macular edema.

Behin Barahimi, MD, discusses some current trends in the treatment of dry eye disease. An oculoplastic, orbital and reconstructive surgeon, she is a member of the faculty at Vanderbilt Eye Institute.